Submitted:
31 July 2025
Posted:
31 July 2025
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. One-Step Growth Curve Determination
2.1. ”Growth” Is the Easy Part
2.2. ”One-Step” Is Trickier
2.3. A Basic One-Step Growth Protocol
[i] A suitable dilution of phage was mixed with a suspension of bacteria containing 2 × 108 organisms per cc. and [ii] allowed to stand at the indicated temperature for 10 minutes to obtain more than 90 per cent adsorption of the phage. [iii] This mixture was then diluted 1:104 in broth, and incubated. [iv] It was again diluted 1:10 at the start of the first rise to further decrease the rate of adsorption of the phage set free in the first step.
- Add phages to a broth culture of experimental bacteria, usually with a starting ratio of added phages to targeted bacteria of one-tenth (0.1) or less. Typically this broth culture will be in mid-log phase, though it is certainly possible to intentionally vary from that.
- Allow for phage adsorption, which ideally will occur over a relatively short span of time, such as a few minutes, and which, as noted by Ellis and Delbrück, ultimately should be fairly complete before proceeding further.
- Prior to the anticipated start of lysis and after sufficient adsorption has occurred, dilute cultures. It is necessary to dilute at this time to minimize the adsorption of released virions to still-present bacteria, thereby avoiding multi-step growth. It also is convenient to perform this dilution prior to the next step, step iv, so as to minimize subsequent diluting before plating. This is a step that seems most often to be missing in published OSG methods, typically leading to the appearance of multi-step rather than single-step growth (Section 3.5.1 and Appendix A).
- It can be both useful and convenient to further dilute cultures in anticipation of phage release, where such release constitutes the phage rise. This dilution step (or steps) especially needs to be precise since any diluting errors at this point will directly impact calculated burst sizes.
- Throughout this process, take samples for plating, starting particularly after step iii. This is the determining-numbers-of-infective-centers step.
2.4. Summary of Dos and Don’ts
- Do run simplified pilot experiments toward subsequent OSG design, including as based on culture turbidity measures alone (4.3).
- Do start with a reasonably fresh phage stock (3.1.2).
- Do titer using fresh (3.1.4), log-phase indicator bacterial strain (3.4.1), which also support a high efficiency of free phage plating (3.1.3).
- Don’t initiate experiments with phage multiplicities of greater than 0.1 (3.2.2).
- Do optimize phage adsorption toward increasing adsorption synchronization (3.2.3).
- Do titer for free phages post-adsorption and/or remove those phages from experimental cultures (3.3.2, 3.3.3, 3.5.4.1).
- Do generate sufficient numbers, e.g., 5, of pre-lysis titer time points (3.4.4, 4.13).
- Do dilute experimental cultures sufficiently to avoid multi-step growth (3.3.4, 3.5.1).
- Don’t dilute experimental cultures so far that too few bacteria are being sampled for lysis (3.3.4).
- Do design dilutions to minimize diluting complications during experiments (Section 4).
- Don’t worry too much about keeping intervals between time points consistent (3.4.3).
- Do increase the number of time points around when lysis (the rise) is expected to take place (3.4.4).
- Do use the point at which the rise has begun to define the end of the constant period (3.4.5), unless the jump in titer is too great (3.3.6), and consider using the trajectory of the rise also or instead to estimate this time point (3.4.5, 3.6.2).
- Don’t claim lysis-timing precision that exceeds the length of intervals between time points (3.4.2, 3.4.5).
- Do keep in mind that the duration of the rise in part is a function of how well initial phage adsorptions were synchronized (3.2.3).
- Do make sure that phage titers have plateaued post-rise (3.5.2).
- Do take multiple time points during the post-rise (3.5.4), such as over a half-hour period.
- Do follow up on unexpectedly or unusually large burst sizes (3.6.3).
- Do present data normalized to average starting phage titers so as to make burst sizes more easily appreciated visually (3.5.3).
- Don’t add chloroform to infective center-containing media at any point during experiments except within a separate containing prior to plating for unadsorbed phages (4.1.2), or if the goal is to define the eclipse (5.3), or instead to validate the post-rise (5.2).
3. One-Step Dos and Don’ts
3.1. Experimental Setup
3.1.1. Use Log Phase Experimental Bacteria
- The experiment was initiated with stationary phase bacteria (“an overnight host”; Section 3.1.1).
- The experimental bacterial culture, at least as indicated, was not diluted during the experiment (Section 3.3.4), except that bacteria were suspended in fresh broth following phage adsorption and removal of free phages via centrifugation.
- Prior to the start of lysis, the number of infective centers rises somewhat, perhaps as we speculate due to phage infections of initially metabolizing stationary phase bacteria being detrimentally affected by the plating process.
- Five-minute time points were used throughout the experiment, including during the rise, resulting in only a single time point definitely capturing the lysis event (Section 3.4.2 and Section 3.4.4).
- Latent period is defined as the last pre-lysis time point, though in one case whether it is prior to or following that time point is ambiguous and in both cases, with five-minute time points it is difficult to say whether the start of lysis actually occurred at the indicated time point or instead occurred a few minutes later (Section 3.4.5).
- The burst size, at least diagrammatically, is defined as the first time point at which titers seem to start to stabilize, possibly post-lysis, rather than involving multiple post-lysis time points (Sections 3.4.4 and 3.5.5?).
- It is difficult for the reader to determine which time points were used to define the post-lysis phage titer in burst-size calculations.
- Phage titers are graphed as seemingly arbitrary values in absolute terms, i.e., starting around 103 PFU/ml. What do these titer values mean?
- Ideally these values would have been normalized to the pre-lysis phage titers in the presented figure (Section 3.5.3).
- Post-rise, the titer does not appear to stabilize but instead continues to increase (Section 3.4.4, Section 3.5.1, and Section 3.5.2).
3.1.2. Start with a Reasonably Fresh Phage Stock
3.1.3. Taking into Account Phage Efficiency of Plating
3.1.4. Start with Fresh Indicator Bacteria
3.2. Phage Adsorption: A Time for Synchronization
3.2.1. Use a Sufficient Concentration of Experimental Bacteria
3.2.2. Use an Appropriate MOI
3.2.3. Synchronization of Adsorption
3.2.4. Routes to Adsorption Synchronization
3.3. Post-Adsorption, Prior to Lysis: The Phage Infection
3.3.1. Infective Centers
3.3.2. Accounting for Free, Unadsorbed Phages
3.3.3. Assessing Unadsorbed Phages
3.3.4. Dilute Enough, but Not Too Much
3.3.5. Reducing Post-Lysis Adsorption
3.3.6. Bacteria Can Lyse During Enumeration
3.4. During Lysis: The Phage Rise
3.4.1. Use Log-Phase Indicator Bacteria
3.4.2. Too Many Time Points Is Preferable to Too Few
3.4.3. It’s Not Essential to Keep Intervals Between Time Points Constant
3.4.4. Take Sufficient Numbers of Time Points at Each Stage
3.4.5. Defining the Constant Period
Or Draw a Line Through the Rise
Or Don’t Define Latent Period as the Constant Period
Which Approach Is Preferable?
3.5. After Lysis: The Post-Rise
3.5.1. Avoid Two- or Multi-Step Growth
3.5.2. Looking for Post-Rise Plateauing
3.5.3. Normalize to Starting Numbers of Plaque-Forming Units
3.5.4. Burst Size Calculation
Subtracting off Unadsorbed Virions
Addressing Outlier Values
Averaging Average Burst Sizes
How Not to Calculate Burst Size
3.6. Summarizing What OSG Data Are Important
3.6.1. Prior to Lysis
3.6.2. During Lysis
3.6.3. After Lysis
4. Making OSG Experiments Easier (and Better)
4.1. Minimizing Dilution Steps per Individual Platings
4.1.1. Adsorbing Then Diluting
4.1.2. Plating For Unadsorbed Phages
4.1.3. Pre-Lysis Platings
4.1.4. Dilute Some More
4.1.5. Cycle Platings Between Dilutions
4.2. Direct Plating Mostly Is Good Enough
4.3. Minimize Number of Platings?
5. Extensions of One-Step Growth Experiments
5.1. Starting with Bacterial Lysogens
5.2. Don’t Use OSG to Characterize Lysis Timing if You Don’t Need to
5.3. Eclipse Period Determination
6. Conclusions
Funding
Acknowledgements
Conflicts of Interest
Appendix A: Examples of One-Step Growth From the Literature





















References
- Adams, M. H. Bacteriophages; InterScience: New York, 1959.
- Ellis, E. L.; Delbrück, M. The growth of bacteriophage. J. Gen. Physiol. 1939, 22, 365-384. [CrossRef]
- Benzer, S.; Hudson, W.; Weidel, W.; Delbrück, M.; Stent, G. S.; Weigle, J. J.; Dulbecco, R.; Watson, J. D.; Wollman, E. L. A syllabus on procedures, facts, and interpretations in phage. In Viruses 1950, Delbrück, M., Ed.; California Institute of Technology: Pasadena, CA, 1950; 100-147.
- Stent, G. S. Molecular Biology of Bacterial Viruses; WH Freeman and Co.: San Francisco, CA, 1963.
- Carlson, K. Single-step growth. In Molecular Biology of Bacteriophage T4, Karam, J. D., Ed.; ASM Press: Washington, 1994; 434-437.
- Hyman, P.; Abedon, S. T. Practical methods for determining phage growth parameters. Meth. Mol. Biol. 2009, 501, 175-202. [CrossRef]
- Kropinski, A. M. Practical advice on the one-step growth curve. Meth. Mol. Biol. 2018, 1681, 41-47. [CrossRef]
- Adams, M. H. Mixed infection with bacterial virus T5 and its heat stable mutant. J. Immunol. 1951, 66, 131-136. [CrossRef]
- Summers, W. C. Bacteriophage research: early research. In Bacteriophages: Biology and Application, Kutter, E.; Sulakvelidze, A., Eds.; CRC Press: Boca Raton, Florida, 2005; 5-28.
- Sankaran, N. Stepping-stones to one-step growth: Frank Macfarlane Burnet’s role in elucidating the viral nature of the bacteriophages. Historical Records of Australian Science 2008, 19, 83-100. [CrossRef]
- Dennehy, J. J.; Abedon, S. T. Phage infection and lysis. In Bacteriophages: Biology, Technology, Therapy, Harper, D., Abedon, S. T., Burrowes, B. H.; McConville, M., Eds.; Springer Nature Switzerland AG: New York City, 2021; 341-383.
- Abedon, S. T. Evolution of bacteriophage latent period length. In Evolutionary Biology: New Perspectives on its Development, Dickins, T. E.; Dickens, B. J. A., Eds.; Springer: Cham, Switzerland, 2023; 375-426.
- Dennehy, J. J.; Abedon, S. T. Adsorption: phage acquisition of bacteria. In Bacteriophages: Biology, Technology, Therapy, Harper, D., Abedon, S. T., Burrowes, B. H.; McConville, M., Eds.; Springer Nature Switzerland AG: New York City, 2021; 93-117.
- Górski, A.; Miedzybrodzki, R.; Borysowski, J. Phage Therapy: A Practical Approach; Springer Nature: Cham, Switzerland, 2019.
- Abedon, S. T.; Danis-Wlodarczyk, K.; Alves, D. R. Phage therapy in the 21st Century: is there modern, clinical evidence of phage-mediated clinical efficacy? Pharmaceuticals 2021, 14, 1157.
- Marongiu, L.; Burkard, M.; Lauer, U. M.; Hoelzle, L. E.; Venturelli, S. Reassessment of historical clinical trials supports the effectiveness of phage therapy. Clin. Microbiol Rev. 2022, 35, e0006222. [CrossRef]
- Suh, G. A.; Lodise, T. P.; Tamma, P. D.; Knisely, J. M.; Alexander, J.; Aslam, S.; Barton, K. D.; Bizzell, E.; Totten, K. M. C.; Campbell, J.; Chan, B. K.; Cunningham, S. A.; Goodman, K. E.; Greenwood-Quaintance, K.; Harris, A. D.; Hesse, S.; Maresso, A.; Nussenblatt, V.; Pride, D.; Rybak, M.; Sund, Z.; van Duin, D.; Van Tyne, D.; Patel, R. Considerations for the use of phage therapy in clinical practice. Antimicrob. Agents Chemother. 2022, 66, AAC0207121.
- Petrovic Fabijan, A.; Iredell, J.; Danis-Wlodarczyk, K.; Kebriaei, R.; Abedon, S. T. Translating phage therapy into the clinic: recent accomplishments but continuing challenges. PLoS Biol. 2023, 21, e3002119. [CrossRef]
- Strathdee, S. A.; Hatfull, G. F.; Mutalik, V. K.; Schooley, R. T. Phage therapy: From biological mechanisms to future directions. Cell 2023, 186, 17-31. [CrossRef]
- Danis-Wlodarczyk, K.; Alves, D.; Abedon, S. T. Phage therapy: a clinician’s guide. In Handbook of Molecular Biology, Liu, D., Ed.; CRC Press: Boca Raton, FL, 2024.
- Kim, M. K.; Suh, G. A.; Cullen, G. D.; Perez, R. S.; Dharmaraj, T.; Chang, T. H. W.; Li, Z.; Chen, Q.; Green, S. I.; Lavigne, R.; Pirnay, J. P.; Bollyky, P. L.; Sacher, J. C. Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches. J Clin. Invest 2025, 135. [CrossRef]
- Dennehy, J. J.; Abedon, S. T. Bacteriophage ecology. In Bacteriophages: Biology, Technology, Therapy, Harper, D., Abedon, S. T., Burrowes, B. H.; McConville, M., Eds.; Springer Nature Switzerland AG: New York City, 2021; 253-294.
- Abedon, S. T. Bacteriophages as Drivers of Evolution: An Evolutionary Ecological Perspective; Springer: Cham, Switzerland, 2022.
- Abedon, S.T. Phage adsorption theory. 2017. https://adsorption.phage.org.
- Abedon, S.T. Phage adsorptions calculator. 2022. https://phage-therapy.org/calculators/adsorptions.html.
- Abedon, S. T. Bacteriophage adsorption: likelihood of virion encounter with bacteria and other factors affecting rates. Antibiotics 2023, 12, 723.
- Antani, J. D.; Ward, T.; Emonet, T.; Turner, P. E. Microscopic phage adsorption assay: high-throughput quantification of virus particle attachment to host bacterial cells. Proc. Natl. Acad. Sci. U. S. A 2024, 121, e2410905121. [CrossRef]
- de Paepe, M.; Taddei, F. Viruses’ life history: towards a mechanistic basis of a trade-off between survival and reproduction among phages. PLoS Biol. 2006, 4, e193.
- Heineman, R. H.; Brown, S. P. Experimental evolution of a bacteriophage virus reveals the trajectory of adaptation across a fecundity/longevity trade-off. PLoS One 2012, 7, e46322.
- Garcia-Villada, L.; Drake, J. W. Experimental selection reveals a trade-off between fecundity and lifespan in the coliphage Qb. Open. Biol. 2013, 3, 130043.
- Payne, R. J. H.; Jansen, V. A. A. Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals. Clin. Pharmacol. Ther. 2000, 68, 225-230. [CrossRef]
- Abedon, S. T.; Thomas-Abedon, C. Phage therapy pharmacology. Curr. Pharm. Biotechnol. 2010, 11, 28-47. [CrossRef]
- Chan, B. K.; Abedon, S. T. Bacteriophage adaptation, with particular attention to issues of phage host range. In Bacteriophages in Dairy Processing, Quiberoni, A.; Reinheimer, J., Eds.; Nova Science Publishers: Hauppauge, New York, 2012; 25-52.
- Weitz, J. S.; Li, G.; Gulbudak, H.; Cortez, M. H.; Whitaker, R. J. Viral invasion fitness across a continuum from lysis to latency. Virus Evol. 2019, 5, vez006.
- Hyman, P.; Abedon, S. T. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol. 2010, 70, 217-248.
- Koskella, B.; Meaden, S. Understanding bacteriophage specificity in natural microbial communities. Viruses 2013, 5, 806-823.
- Dabrowska, K.; Abedon, S. T. Pharmacologically aware phage therapy: pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies. Microbiol. Mol. Biol. Rev. 2019, 83, e00012-19. [CrossRef]
- Gencay, Y. E.; Gambino, M.; From, P. T.; Brondsted, L. The genera of bacteriophages and their receptors are the major determinants of host range. Environ. Microbiol. 2019, 21, 2095-2111. [CrossRef]
- Hyman, P. Phages for phage therapy: isolation, characterization, and host range breadth. Pharmaceuticals 2019, 12, 35.
- Abedon, S. T.; Danis-Wlodarczyk, K. M.; Wozniak, D. J. Phage cocktail development for bacteriophage therapy: toward improving spectrum of activity breadth and depth. Pharmaceuticals 2021, 14, 1019. [CrossRef]
- Lamy-Besnier, Q.; Brancotte, B.; Menager, H.; Debarbieux, L. Viral Host Range database, an online tool for recording, analyzing and disseminating virus-host interactions. Bioinformatics 2021, 60, 921-925.
- Middelboe, M.; Chan, A.M.; Bertelsen, S.K. One-step growth experiments (bacteriophages). 2016. [CrossRef]
- Kutter, E. Phage host range and efficiency of plating. Meth. Mol. Biol. 2009, 501, 141-149.
- Letarov, A. V.; Kulikov, E. E. Determination of the bacteriophage host range: culture-based approach. Meth. Mol. Biol. 2018, 1693, 75-84.
- Hadas, H.; Einav, M.; Fishov, I.; Zaritsky, A. Bacteriophage T4 development depends on the physiology of its host Escherichia coli. Microbiology 1997, 143, 179-185. [CrossRef]
- Carlson, K. Working with bacteriophages: common techniques and methodological approaches. In Bacteriophages: Biology and Application, Kutter, E.; Sulakvelidze, A., Eds.; CRC Press: Boca Raton, Florida, 2005; 437-494.
- Lanni, F. Small reversible clumps of bacteriophage and their anomalous serologic behavior. J. Immunol. 1959, 83, 148-166.
- Abedon, S. T. Phage therapy dosing: the problem(s) with multiplicity of infection (MOI). Bacteriophage 2016, 6, e1220348. [CrossRef]
- Abedon, S. T. Multiplicity of infection. In Reference Module in Life Sciences, Elsevier: 2017.
- Abedon, S.T. Multiplicity of infection calculator. 2017. https://moicalculator.phage.org.
- Abedon, S. T. Look who’s talking: T-even phage lysis inhibition, the granddaddy of virus-virus intercellular communication research. Viruses 2019, 11, 951. [CrossRef]
- Abedon, S. T. How simple maths can inform our basic understanding of phage therapy. Clin. Infect. Dis. 2023, 77, S401-S406.
- Abedon, S. T.; Katsaounis, T. I. Basic phage mathematics. Meth. Mol. Biol. 2018, 1681, 3-30.
- Abedon, S.T. Poisson frequencies calculator. 2022. https://www.phage.org/calculators/Poisson.html.
- Abedon, S. T. Further considerations on how to improve phage therapy experimentation, practice, and reporting: pharmacodynamics perspectives. Phage 2022, 3, 98-111.
- Abedon, S. T. Automating predictive phage therapy pharmacology. Antibiotics (Basel) 2023, 12, 1423.
- Gadagkar, R.; Gopinathan, K. P. Bacteriophage burst size during multiple infections. J. Biosci. 1980, 2, 253-259. [CrossRef]
- Wedd, C.; Yunusov, T.; Smith, A.; Li, R.; Hardo, G.; Hunter, M.; Majed, R.; Fusco, D.; Bakshi, S. Single-cell imaging of the lytic phage life cycle in bacteria. bioRxiv 2024, 2024-04.
- Delbrück, M. The burst size distribution in the growth of bacterial viruses (bacteriophages). J. Bacteriol. 1945, 50, 131-135.
- Abedon, S. T.; Danis-Wlodarczyk, K. M.; Wozniak, D. J.; Sullivan, M. B. Improving phage-biofilm in vitro experimentation. Viruses 2021, 13, 1175. [CrossRef]
- Doermann, A. H. Intracellular phage growth as studied by premature lysis. Federation Proc. 1951, 10, 591-594.
- Anderson, T. F.; Doermann, A. H. The intracellular growth of bacteriophages. II. The growth of T3 studied by sonic disintegration and by T6-cyanide lysis of infected cell. J. Gen. Physiol. 1952, 35, 657-667.
- Abedon, S. T.; Katsaounis, T. I. Detection of bacteriophages: statistical aspects of plaque assay. In Bacteriophages: Biology, Technology, Therapy, Harper, D., Abedon, S. T., Burrowes, B. H.; McConville, M., Eds.; Springer Nature Switzerland AG: New York City, 2021; 539-560.
- Jongenburger, I.; Reij, M. W.; Boer, E. P.; Gorris, L. G.; Zwietering, M. H. Factors influencing the accuracy of the plating method used to enumerate low numbers of viable micro-organisms in food. Int. J Food Microbiol 2010, 143, 32-40.
- Kropinski, A. M.; Mazzocco, A.; Waddell, T. E.; Lingohr, E.; Johnson, R. P. Enumeration of bacteriophages by double agar overlay plaque assay. Meth. Mol. Biol. 2009, 501, 69-76.
- Delbruck, M. Adsorption of bacteriophage under various physiological conditions of the host. J. Gen. Physiol. 1940, 23, 631-642. [CrossRef]
- Wassermann, F. E. A Study of the Genetic Relationship Between the Coli-Dysentery Bacteriophage-T5 and the Salmonella Bacteriophage-Pb. Ph.D. New York University, 1958.
- Garbe, J.; Wesche, A.; Bunk, B.; Kazmierczak, M.; Selezska, K.; Rohde, C.; Sikorski, J.; Rohde, M.; Jahn, D.; Schobert, M. Characterization of JG024, a Pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions. BMC Microbiol. 2010, 10, 301.
- Pelzek, A. J.; Schuch, R.; Schmitz, J. E.; Fischetti, V. A. Isolation, culture, and characterization of bacteriophages. Current Protocols Essential Laboratory Techniques 2013, 7, 4.
- Goyal, P.; Mathur, N.; Singh, A.; Singh, K.; Mohammad, I. Isolation, Characterization and In vivo Evaluation of Therapeutic Potential of Bacteriophage Sal11TP against Salmonella enterica Serovar Paratyphi A. Journal of Pure & Applied Microbiology 2025, 19, 128-140.
- Abedon, S. T. Bacteriophage secondary infection. Virol. Sin. 2015, 30, 3-10.
- d’Hérelle, F.; Smith, G. H. The Bacteriophage and Its Behavior [English translation]; The Williams &Wilkins Co.: Baltimore, 1926.
- Abedon, S. T.; Duffy, S.; Turner, P. E. Bacteriophage ecology. In Encyclopedia of Microbiology, Schaecter, M., Ed.; Elsevier: Oxford, 2009; 42-57.
- Turner, P. E.; Draghi, J. A.; Wilpiszeski, R. High-throughput analysis of growth differences among phage strains. J. Microbiol. Meth. 2012, 88, 117-121.
- Doermann, A. H. Intracellular phage growth as studied by premature lysis. Federation Proc. 1951, 10, 591-594. [CrossRef]
- Doermann, A. H. The intracellular growth of bacteriophages I. liberation of intracellular bacteriophage T4 by premature lysis with another phage or with cyanide. Journal of General Physiology 1952, 35, 645-656.
- Amarillas, L.; Chaidez, C.; Gonzalez-Robles, A.; Lugo-Melchor, Y.; Leon-Felix, J. Characterization of novel bacteriophage phiC119 capable of lysing multidrug-resistant Shiga toxin-producing Escherichia coli O157:H7. PeerJ. 2016, 4, e2423.
- Wang, Z.; Zhao, J.; Wang, L.; Li, C.; Liu, J.; Zhang, L.; Zhang, Y. A novel benthic phage infecting Shewanella with strong replication ability. Viruses 2019, 11, 1081.
- Liao, Y. T.; Zhang, Y.; Salvador, A.; Ho, K. J.; Cooley, M. B.; Wu, V. C. H. Characterization of polyvalent Escherichia phage Sa157lw for the biocontrol potential of Salmonella Typhimurium and Escherichia coli O157:H7 on contaminated mung bean seeds. Front. Microbiol. 2022, 13, 1053583. [CrossRef]
- Fiers, W. Structure and function of RNA bacteriophages. In Comprehensive Virology Volume 13: Structure and Assembly: Primary, Secondary, Tertiary, and Quaternary Structures, Fraenkel-Conrat, H.; Wagner, R. R., Eds.; Springer: 1979; 69-204.
- Danis-Wlodarczyk, K. M.; Cai, A.; Chen, A.; Gittrich, M. R.; Sullivan, M. B.; Wozniak, D. J.; Abedon, S. T. Friends or foes? Rapid determination of dissimilar colistin and ciprofloxacin antagonism of Pseudomonas aeruginosa phages. Pharmaceuticals 2021, 14, 1162.
- Jacob, F.; Wollman, E. L. Lysogeny. In The Viruses: Biochemical, Biological and Biophysical Properties: Plant and Bacterial Viruses, Burnet, F. M.; Stanley, W. M., Eds.; Academic Press: New York, 1959; 319-351.
- Abedon, S. T.; Hyman, P.; Thomas, C. Experimental examination of bacteriophage latent-period evolution as a response to bacterial availability. Appl. Environ. Microbiol. 2003, 69, 7499-7506. [CrossRef]
- Mittler, J. E. Evolution of the genetic switch in temperate bacteriophage. I. Basic theory. J. Theor. Biol. 1996, 179, 161-172. [CrossRef]
- Bertani, G. Lysogenic versus lytic cycle of phage multiplication. Cold Spring Harbor Symp. Quant. Biol. 1953, 18, 65-70.
- Yasbin, R. E.; Ganesan, A. T.; Young, F. E. Bacteriophage interference in Bacillus subtilis 168. J Virol. 1974, 13, 916-921.
- Rolfe, B. G.; Campbell, J. H. Genetic and physiological control of host cell lysis by bacteriophage lambda. J. Virol. 1977, 23, 626-636.
- Garrett, J. M.; Fusselman, R.; Hise, J.; Chiou, L.; Smith-Grillo, D.; Schultz, J.; Young, R. Cell lysis by induction of cloned lambda lysis genes. Mol. Gen. Genet. 1981, 182, 326-331.
- Rajnovic, D.; Munoz-Berbel, X.; Mas, J. Fast phage detection and quantification: An optical density-based approach. PLoS One 2019, 14, e0216292.
- Doermann, A. H. Intracellular growth of bacteriophage. Year Book Carnegie Inst. Wash. 1948, 47, 176-182.
- Doermann, A. H. The eclipse in the bacteriophage life cycle. In Phage and the Origins of Molecular Biology (expanded edition), Cairns, J., Stent, G. S.; Watson, J. D., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1966; 79-87.
- Valappil S.K.; Shetty, P.; Deim, Z.; Terhes, G.; Urban, E.; Vaczi, S.; Patai, R.; Polgar, T.; Pertics, B. Z.; Schneider, G.; Kovacs, T.; Rakhely, G. Survival comes at a cost: a coevolution of phage and its host leads to phage resistance and antibiotic sensitivity of Pseudomonas aeruginosa multidrug resistant strains. Front Microbiol. 2021, 12, 783722.
- Storms, Z. J.; Sauvageau, D. Evidence that the heterogeneity of a T4 population is the result of heritable traits. PLoS One 2014, 9, e116235. [CrossRef]
- Stone, E.; Lhomet, A.; Neve, H.; Grant, I. R.; Campbell, K.; McAuliffe, O. Isolation and characterization of Listeria monocytogenes phage vB_LmoH_P61, a phage with biocontrol potential on different food matrices. Frontiers in Sustainable Food Systems 2020, 4, 521645.
- Denes, T.; den Bakker, H. C.; Tokman, J. I.; Guldimann, C.; Wiedmann, M. Selection and characterization of phage-resistant mutant strains of Listeria monocytogenes reveal host genes linked to phage adsorption. Appl. Environ. Microbiol. 2015, 81, 4295-4305.
- Lu, S.; Le, S.; Tan, Y.; Zhu, J.; Li, M.; Rao, X.; Zou, L.; Li, S.; Wang, J.; Jin, X. Genomic and proteomic analyses of the terminally redundant genome of the Pseudomonas aeruginosa phage PaP1: establishment of genus PaP1-like phages. PLoS One 2013, 8, e62933. [CrossRef]
- Liu, J.; Zhu, Y.; Li, Y.; Lu, Y.; Xiong, K.; Zhong, Q.; Wang, J. Bacteriophage-resistant mutant of Enterococcus faecalis Is impaired in biofilm formation. Front. Microbiol. 2022, 13, 913023.
- Han, K.; Dong, Y.; An, X.; Song, L.; Li, M.; Fan, H.; Tong, Y. Potential application of a newly isolated phage BUCT609 infecting Stenotrophomonas maltophilia. Front. Microbiol. 2022, 13, 1001237. [CrossRef]
- Gilcrease, E. B.; Casjens, S. R.; Bhattacharjee, A.; Goel, R. A Klebsiella pneumoniae NDM-1+ bacteriophage: adaptive polyvalence and disruption of heterogenous biofilms. Front. Microbiol. 2023, 14, 1100607.
- Tang, M.; Huang, Z.; Zhang, X.; Kong, J.; Zhou, B.; Han, Y.; Zhang, Y.; Chen, L.; Zhou, T. Phage resistance formation and fitness costs of hypervirulent Klebsiella pneumoniae mediated by K2 capsule-specific phage and the corresponding mechanisms. Front. Microbiol. 2023, 14, 1156292.
- Sun, W. J.; Liu, C. F.; Yu, L.; Cui, F. J.; Zhou, Q.; Yu, S. L.; Sun, L. A novel bacteriophage KSL-1 of 2-Keto-gluconic acid producer Pseudomonas fluorescens K1005: isolation, characterization and its remedial action. BMC Microbiol. 2012, 12, 127.
- Melo, L. D. R.; Ferreira, R.; Costa, A. R.; Oliveira, H.; Azeredo, J. Efficacy and safety assessment of two enterococci phages in an in vitro biofilm wound model. Sci. Rep. 2019, 9, 6643.
- Corban, J. E.; Ramsey, J. Characterization and complete genome sequence of Privateer, a highly prolate Proteus mirabilis podophage. PeerJ. 2021, 9, e10645.
- Koonjan, S.; Seijsing, F.; Cooper, C. J.; Nilsson, A. S. Infection kinetics and phylogenetic analysis of vB_EcoD_SU57, a virulent T1-like drexlerviridae coliphage. Front. Microbiol. 2020, 11, 565556.
- He, P.; Cao, F.; Qu, Q.; Geng, H.; Yang, X.; Xu, T.; Wang, R.; Jia, X.; Lu, M.; Zeng, P.; Luan, G. Host range expansion of Acinetobacter phage vB_Ab4_Hep4 driven by a spontaneous tail tubular mutation. Front. Cell. Infect. Microbiol. 2024, 14, 1301089.
- Muliya Sankappa, N.; Kallappa, S. G.; Kallihosuru Boregowda, K. Novel lytic bacteriophage AhFM11 as an effective therapy against hypervirulent Aeromonas hydrophila. Sci. Rep. 2024, 14, 16882.
- Sun, Z.; Mandlaa; Wen, H.; Ma, L.; Chen, Z. Isolation, characterization and application of bacteriophage PSDA-2 against Salmonella Typhimurium in chilled mutton. PLoS One 2022, 17, e0262946.
- Banar, M.; Kamyab, H.; Torkashvand, N.; Zahraei, S. T.; Sepehrizadeh, Z.; Shahverdi, A. R.; Pourmand, M. R.; Yazdi, M. H. A novel broad-spectrum bacteriophage cocktail against methicillin-resistant Staphylococcus aureus: Isolation, characterization, and therapeutic potential in a mastitis mouse model. PLoS One 2025, 20, e0316157.
- Chai, J.; Sun, H.; Schwarz, S.; Huang, Y.; Xie, S.; Xu, Q.; Lin, L.; Ma, C.; Hou, J.; Zhu, Y.; Zhang, W. Isolation, characterization, and application of the novel polyvalent bacteriophage vB_EcoM_XAM237 against pathogenic Escherichia coli. Vet. Res. 2025, 56, 90.
- Bulssico, J.; Papukashvili, I.; Espinosa, L.; Gandon, S.; Ansaldi, M. Phage-antibiotic synergy: Cell filamentation is a key driver of successful phage predation. PLoS Pathog. 2023, 19, e1011602. [CrossRef]



| Phase, Period, or Term | Definition | Comments | Section(s) |
|---|---|---|---|
| Infective center | Either a free virion or a phage-infected bacterium that is able to form a plaque | Synonym: plaque-forming unit (PFU) | 3.3.1 |
| Adsorption | Time during which free virions are converted into bacteria-infecting phages | This should be intentionally limited in duration | 3.2 |
| Eclipse | Time during latent period prior to the intracellular formation of the first mature virion | It is not possible to define the eclipse using a standard, without artificial lysis OSG protocol | 3.3, 3.6.1, and 5.3 |
| Post-Eclipse | Time during the latent period the latent period that follows the eclipse and which ends with phage-induced bacterial lysis | We are not aware of an agreed upon name for this period; the length of this period, too, is not definable using a standard OSG protocol | 3.3, 3.6.1, and 5.3 |
| Rise | Time during which lysis across a population of phage-infected bacteria is occurring, seen as an increase in the phage titer of a culture that has a well-defined start and finish | If the rise does not have obvious end point, such that titers keep rising, then that is an indication of multi-step growth; synonyms: Burst period or burst time | 3.4 and 3.6.2 |
| Post-Rise | Time following the rise during which titers have stabilized (neither substantially rising nor falling) | If titers start to increase again post-rise, then that is an indication of multi-step growth; synonyms: Post-lysis, Plateau | 3.5 and 3.6.3 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).